GABA Receptor Antagonists – Pipeline Insight, 2020
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “GABA Receptor Antagonists – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in GABA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
GABA Receptor Antagonists: Overview
Gamma-aminobutyric acid (GABA) inhibitors, or GABA antagonists, are drugs which inhibit the action of GABA, the primary inhibitory neurotransmitter of the central nervous system. They predominantly work at the GABA receptor. GABA receptors categorize into the GABA-A receptor and GABA-B receptor subtypes. There also exists a GABA-C receptor, but it is typically classified as a subtype of GABA-A receptors and named GABA-A-rho. While GABA-A receptors are ionotropic receptors that gate chloride channels, GABA-B receptors are metabotropic G-protein coupled receptors. The receptor subtypes can also be differentiated based on their selectivity to agonists and antagonists: GABA-A receptors are antagonized by bicuculline and insensitive to baclofen, whereas GABA-B receptors are agonized by baclofen and insensitive to bicuculline. The potency of most GABA-A receptor antagonists is mostly independent of receptors subunit composition, in contrast to GABA-A receptor agonists.
This segment of the GABA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA Receptor Antagonists Emerging Drugs
Further product details are provided in the report……..
GABA Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different GABA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
GABA Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses GABA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA Receptor Antagonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “GABA Receptor Antagonists – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in GABA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
GABA Receptor Antagonists: Overview
Gamma-aminobutyric acid (GABA) inhibitors, or GABA antagonists, are drugs which inhibit the action of GABA, the primary inhibitory neurotransmitter of the central nervous system. They predominantly work at the GABA receptor. GABA receptors categorize into the GABA-A receptor and GABA-B receptor subtypes. There also exists a GABA-C receptor, but it is typically classified as a subtype of GABA-A receptors and named GABA-A-rho. While GABA-A receptors are ionotropic receptors that gate chloride channels, GABA-B receptors are metabotropic G-protein coupled receptors. The receptor subtypes can also be differentiated based on their selectivity to agonists and antagonists: GABA-A receptors are antagonized by bicuculline and insensitive to baclofen, whereas GABA-B receptors are agonized by baclofen and insensitive to bicuculline. The potency of most GABA-A receptor antagonists is mostly independent of receptors subunit composition, in contrast to GABA-A receptor agonists.
- Examples of GABA-A receptor antagonists include flumazenil, bicuculline, picrotoxin/picrotoxinin, gabazine, suramin, sepranolone, salicylidene salicylhydrazide (SCS), bilobalide, RU5135, and 4-(3-biphenyl-5-(4-piperidyl)-3-isoxazole (3-biphenyl-4-PIOL). Examples of GABA-C receptor antagonists include 1,2,5,6-Tetrahydropyridin-4-methylphosphinic acid (TPMPA).
- GABA receptor antagonists produce convulsant and stimulant effects and mainly have a use for research purposes. For example, bicuculline and gabazine are frequently used to dissect GABA-A receptor components in neurons functionally. These GABA receptor antagonists act as subtype-selective compounds and help to study the behavioral effects of the different GABA-A receptor subtypes.
- The major inhibitory neurotransmitter in the central nervous system (CNS) is the gamma?amino butyric acid (GABA). Inhibition is mediated by the ionotropic and metabotropic receptors, located pre or postsynaptically.
This segment of the GABA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA Receptor Antagonists Emerging Drugs
- Golexanolone: Umecrine Cognition
Further product details are provided in the report……..
GABA Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different GABA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on GABA Receptor Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
GABA Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses GABA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA Receptor Antagonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence GABA Receptor Antagonists R&D. The therapies under development are focused on novel approaches for GABA Receptor Antagonists.
- February 2020: Cerecor announced it had completed the previously announced acquisition of Aevi Genomic Medicine in an all-stock transaction valued at approximately USD 15.6 million at close, plus contingent value rights (CVRs) for up to an additional USD 6.5 million in subsequent payments based on clinical and/or regulatory milestones. Cerecor’s pipeline now includes six clinical-stage assets, accelerating the Company’s transformation into a research and development organization focused on developing new medicines for unmet needs in rare diseases, particularly for pediatric patients. The Company continues to explore strategic alternatives for its non-core neurological assets, including CERC-301, as well as its sole commercialized product, Millipred.
- GABA Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing GABA Receptor Antagonists drugs?
- How many GABA Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for GABA Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for GABA Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Servier
- Umecrine Cognition
- Angelini
- SGS 742
- Afizagabar
- Golexanolone
- Gabapentin/trazodone hydrochloride
Introduction
Executive Summary
GABA Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
GABA Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
GABA Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
GABA Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Golexanolone: Umecrine Cognition
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
GABA Receptor Antagonists Key Companies
GABA Receptor Antagonists Key Products
GABA Receptor Antagonists- Unmet Needs
GABA Receptor Antagonists- Market Drivers and Barriers
GABA Receptor Antagonists- Future Perspectives and Conclusion
GABA Receptor Antagonists Analyst Views
GABA Receptor Antagonists Key Companies
Appendix
Executive Summary
GABA Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
GABA Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
GABA Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
GABA Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Golexanolone: Umecrine Cognition
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
GABA Receptor Antagonists Key Companies
GABA Receptor Antagonists Key Products
GABA Receptor Antagonists- Unmet Needs
GABA Receptor Antagonists- Market Drivers and Barriers
GABA Receptor Antagonists- Future Perspectives and Conclusion
GABA Receptor Antagonists Analyst Views
GABA Receptor Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for GABA Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for GABA Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for GABA Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for GABA Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
